

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

HaystackAnalytics secures patent for cutting-edge secure genomic analysis technology

11 March 2025 | News

Patented technology eliminates the need for high-performance computing and specialised personnel



In a country like India, with a rapidly advancing healthcare landscape and a growing focus on equitable access to enhance disease diagnosis and personalized treatment, Mumbai-based startup HaystackAnalytics, a pioneer in genomics-based diagnostic solutions, has secured a patent for its groundbreaking invention, "Systems and Methods for Secure Genomic Analysis Using a Specialised Edge Computing Device."

This patent marks a significant advance, enabling real-time genomic analysis at the point of use, reducing reliance on complex infrastructure and specialized personnel. It empowers laboratories and hospital labs with real time reporting capabilities with accurate, simplified and timely insights for enhanced patient diagnosis and treatment.

HaystackAnalytics holds exclusive rights to this patent for the next 20 years and is committed to integrating it into all its solutions while making it widely accessible. As genomic sequencing becomes more widespread, the lack of standardised analysis tools has been a major bottleneck. This patent allows real-time sequencing data analysis, minimizing dependence on bioinformatics experts and complex infrastructure.

With rising concerns over antimicrobial resistance (AMR), tuberculosis (TB), and emerging infectious diseases, India urgently needs scalable genomic tools that can be seamlessly deployed in hospitals and labs without complex setup requirements. This milestone reinforces the company's commitment to advancing genomic diagnostics, ensuring standardised, cutting-edge analysis is accessible across diverse healthcare settings. By collaborating with its network of 250+diagnostic labs, 100+ hospitals, and potential public and private healthcare partners, the IIT-B-based company aims to establish this technology as a cornerstone of precision medicine on a global scale.